⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethane SCHEMBL8949825 | 0.95 | CA2 (0.58) | — | |
| Methane SCHEMBL10582767 | 0.95 | — | — | |
| Methylamine SCHEMBL9161531 | 0.91 | CA2 (0.54) | — | |
| Cyclopentane SCHEMBL8949945 | 0.88 | CA2 (0.50) | — | |
| Cyclohexane SCHEMBL8949815 | 0.88 | CA2 (0.50) | — | |
| SCHEMBL11693410 | 0.80 | — | — | |
| SCHEMBL102311 | 0.78 | — | — | |
| Methyl Phosphonate SCHEMBL29461628 | 0.78 | CA2 (1.00) | — | |
| Methyl Phosphonate SCHEMBL21791 | 0.78 | — | — | |
| Methyl Phosphonate SCHEMBL4621163 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0573604-A1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS. | NORWICH EATON PHARMA (US) | 1993-12-15 | — | — | EP | claimed |
| WO-1992014474-A1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1992-09-03 | — | — | WO | claimed |
| US-6329354-B1 | ADMINISTERING BONE ACTIVE PHOSPHONATE, ADMINISTERING ESTROGEN HORMONE | THE PROCTER & GAMBLE COMPANY | 2001-12-11 | — | — | US | disclosed |
| EP-1158987-A1 | METHODS OF INCREASING BONE VOLUME USING NON-NATURALLY-OCCURRING FP SELECTIVE AGONISTS AND ANTIRESORPTIVE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000051617-A1 | METHODS OF INCREASING BONE VOLUME USING NON-NATURALLY-OCCURRING FP SELECTIVE AGONISTS AND ANTIRESORPTIVE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
| US-5712261-A | Method for preventing or treating hypertriglyceridemia | BRISTOL-MYERS SQUIBB COMPANY | 1998-01-27 | — | — | US | disclosed |
| US-5574024-A | Methylene phosphonoalkylphosphinates, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism | EBETINO FRANK H (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0537008-B1 | Use of biphosphonates for the manufacture of a medicament for blocking neoplastic transformation of cells induced by ras oncogenes | SQUIBB & SONS INC (US) | 1995-10-25 | — | — | EP | disclosed |
| US-5428028-A | Method for lowering cholesterol employing a phosphonomethylphosphinate squalene synthetase inhibitor | E. R. SQUIBB & SONS, INC. (US) | 1995-06-27 | — | — | US | disclosed |
| US-5428028-A | Method for lowering cholesterol employing a phosphonomethylphosphinate squalene synthetase inhibitor | E. R. SQUIBB & SONS, INC. (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0573604-B1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS | PROCTER & GAMBLE PHARMA (US) | 1995-03-15 | — | — | EP | disclosed |
| EP-0537008-A1 | Use of biphosphonates for the manufacture of a medicament for blocking neoplastic transformation of cells induced by ras oncogenes | E.R. SQUIBB & SONS, INC. (US) | 1993-04-14 | — | — | EP | disclosed |
| EP-0514124-A2 | Use of phosphonomethylphosphinate squalene synthetase inhibitors for the manufacture of a medicament for the lowering cholesterol | E.R. SQUIBB & SONS, INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| EP-0514124-A2 | Use of phosphonomethylphosphinate squalene synthetase inhibitors for the manufacture of a medicament for the lowering cholesterol | E.R. SQUIBB & SONS, INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| EP-0298553-B1 | METHYLENE PHOSPHONOALKYLPHOSPHINATES, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | Norwich Eaton Pharmaceuticals, Inc. (US) | 1992-01-15 | — | — | EP | disclosed |
| EP-0298553-A1 | Methylene phosphonoalkylphosphinates, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism | Norwich Eaton Pharmaceuticals, Inc. (US) | 1989-01-11 | — | — | EP | disclosed |